Thursday, May 12, 2016

6:00 p.m.-7:30 p.m.  
Opening Plenary Session  
Coquina North  
Welcome from the chairpersons  
Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA  
Opening remarks from the lead supporters  
Julie M. Fleshman, Pancreatic Cancer Action Network  
Kerri Kaplan, Lustgarten Foundation  
Perspective from a patient  
Anne Glauber  
Opening keynote address: Title to be announced  
Chairperson: Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, NY  
Andrew V. Blankin, University of Glasgow, Glasgow, Scotland

7:30 p.m.-9:00 p.m.  
Opening Reception  
Coquina South

Friday, May 13, 2016

7:30 a.m.-8:30 a.m.  
Breakfast and Roundtable Discussions  
Valencia Terrace

8:30 a.m.-10:15 a.m.  
Plenary Session 1: Epidemiology and Risk Factors  
Coquina North  
Chairperson: Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA  
Identification of familial pancreatic cancer susceptibility genes  
Nicholas J. Roberts, Johns Hopkins University, Baltimore, MD  
Genetic and non-genetic risk factors of pancreatic cancer  
Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN  
Pancreatic cancer etiology: Digging into the unknown  
Núria Malats, Spanish National Cancer Center (CNIO), Madrid, Spain  
Patients with severe chronic pancreatitis contain widespread and numerous pancreatic cancer-related somatic variants as detected by picodroplet-enabled targeted sequencing  
Robert W. Cowan, University of Michigan, Ann Arbor, MI

10:15 a.m.-10:45 a.m.  
Break  
Coquina South
10:45 a.m.-12:15 p.m.  Plenary Session 2: Early Detection
Coquina North
Chairperson: Kimberly A. Kelly, University of Virginia, Charlottesville, VA
Title to be announced
Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, TX
Serum contains enough information for early detection of pancreatic cancer
Carl Borrebaeck, Lund University, Lund, Sweden
Stroma: The key to earlier detection?
Kimberly A. Kelly, University of Virginia, Charlottesville, VA

12:15 p.m.-2:45 p.m.  Lunch (on own)

2:45 p.m.-4:30 p.m.  Plenary Session 3: Innovations and New Directions in Pancreatic Cancer Therapy
Coquina North
Chairperson: Channing J. Der, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Drugging undruggable KRAS: Will MYC do the trick?
Channing J. Der, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Role of stereotactic body radiation therapy in patients with locally advanced and borderline resectable pancreas cancer
Joseph M. Herman, Johns Hopkins University, Baltimore, MD

5:00 p.m.-6:00 p.m.  Keynote Address
Coquina North
Chairperson: Robert H. Vonderheide, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
Biomarker selected therapy for pancreas ductal adenocarcinoma: An emerging reality?
Eileen M. O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY
Saturday, May 14, 2016

7:30 a.m.-8:30 a.m.  Breakfast and Roundtable Discussions
Valencia Terrace

8:30 a.m.-10:30 a.m.  Plenary Session 4: Preclinical Drug Development for Pancreatic Cancer
Coquina North
Chairperson: David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Pancreatic cancer biology and medicine
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Applications of PDX models in preclinical PDAC drug development
Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA

Stromal regulation and therapeutic targeting of the pancreatic cancer epigenome
Mara H. Sherman, Salk Institute for Biological Studies, La Jolla, CA

Genome-scale CRISPR-Cas9 screening to identify essential genes and pathways in pancreatic cancer
Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, MA

10:30 a.m.-11:00 a.m.  Break
Coquina South

11:00 a.m.-1:00 p.m.  Plenary Session 5: Heterogeneity of Pancreatic Cancer
Coquina North
Chairperson: Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, NY

Heterogeneity of pancreatic cancer genomes: New insights
Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, NY

Deconstructing pancreatic cancer
Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

Reconstructing compartment-specific regulatory programs in pancreatic cancer
Kenneth P. Olive, Columbia University Irving Comprehensive Cancer Center, New York, NY

The global phospho-proteome of K-Ras mutant cells and tissues
Kevin M. Haigis, Beth Israel Deaconess Medical Center, Boston, MA

1:00 p.m.-4:00 p.m.  Poster Session B and Lunch
Coquina South
4:00 p.m.-6:15 p.m.  Plenary Session 6: Molecular Drivers of Pancreatic Cancer Biology and Metastasis  
Coquina North  
Chairperson: Ben Z. Stanger, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA  
Probing tumor heterogeneity with mouse models  
Ben Z. Stanger, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA  
Defining the balance between division and dissemination in pancreas cancer  
Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, WA  
Biological drivers of pancreatic cancer  
Dafna Bar-Sagi, New York University Langone Medical Center, New York, NY  
Deconstructing p53 transcriptional networks in pancreatic cancer suppression  
Laura D. Attardi, Stanford University, Stanford, CA  
Hypoxia-induced Blimp1 expression induces a transient metastatic heterogeneity in pancreatic cancer  
Monte M. Winslow, Stanford University School of Medicine, Stanford, CA  
Loss of SIRT6 reactivates the RNA-binding protein Lin28b to drive pancreatic cancer  
Sita Kugel, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

Sunday, May 15, 2016

7:30 a.m.-8:30 a.m.  Breakfast and Mentoring Roundtables  
Valencia Terrace

8:30 a.m.-10:30 a.m.  Plenary Session 7: Immune Drug Development  
Coquina North  
Chairperson: Marina Pasca Di Magliano, University of Michigan, Ann Arbor, MI  
Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immune-suppressive environment in pancreatic cancer  
Marina Pasca Di Magliano, University of Michigan, Ann Arbor, MI  
Reprogramming the tumor microenvironment to improve responses to immunotherapy  
David G. DeNardo, Washington University School of Medicine, St. Louis, MO  
Immune landscape of human pancreatic cancer  
Robert H. Vonderheide, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA  
CXCR2 inhibition suppresses metastasis and improves the response to immunotherapy in pancreatic cancer  
Jennifer P. Morton, Cancer Research UK Beatson Institute, Glasgow, United Kingdom  
Dual CCR2/CXCR2 chemokine receptor blockade prevents tumor compensatory myeloid recruitment in pancreatic cancer  
Timothy M. Nywening, Washington University, St. Louis, MO
10:30 a.m.-11:00 a.m.  Break  
Coquina South

11:00 a.m.-1:00 p.m.  Plenary Session 8: Big Picture/Wrap-up Panel Discussion  
Coquina North  
**Moderator:** Robert H. Vonderheide, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA  
**Panelists:**  
Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN  
Jonathan R. Brody, Thomas Jefferson University, Philadelphia, PA  
Lynn Matrisian, Pancreatic Cancer Action Network, Manhattan Beach, CA  
Allyson J. Ocean, Weill Cornell Medical Center, New York, NY  
Q&A

1:00 p.m.  Closing Remarks and Departure